Geneva Capital Management LLC Sells 1,415 Shares of Edwards Lifesciences Co. (NYSE:EW)

Geneva Capital Management LLC lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,322 shares of the medical research company’s stock after selling 1,415 shares during the quarter. Geneva Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,077,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences during the second quarter worth $29,000. Webster Bank N. A. bought a new stake in Edwards Lifesciences during the second quarter worth $39,000. Versant Capital Management Inc lifted its holdings in Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares during the period. Finally, HHM Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the second quarter worth $55,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on EW. Deutsche Bank Aktiengesellschaft dropped their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. The Goldman Sachs Group reduced their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Morgan Stanley restated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Finally, Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $75.67.

Insiders Place Their Bets

In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,250 shares of company stock worth $2,744,438. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.1 %

Shares of NYSE:EW opened at $66.52 on Thursday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a market cap of $39.23 billion, a PE ratio of 9.60, a P/E/G ratio of 3.70 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock’s 50-day moving average is $67.47 and its 200 day moving average is $76.51.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 EPS. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.